Omada Health turns profitable as Q4 revenue beats estimates by 37%
Digital health company's first adjusted EBITDA profit drives 2026 guidance higher on surging GLP-1 member base
Omada Health shares surged in after-hours trading after the virtual care company reported its first profitable quarter and delivered revenue that exceeded analyst estimates by nearly 37%, marking a significant milestone in its transition from loss-making growth to sustainable profitability.
The San Francisco-based company reported fourth-quarter adjusted earnings per share of $0.08, handily beating the loss of $0.09 that analysts had expected, according to data from the company's investor relations site. Revenue of $75.8 million topped the $55.5 million consensus estimate, representing a 36.7% upside surprise.
Perhaps more importantly for investors, Omada achieved its first positive adjusted EBITDA of $6 million, a dramatic turnaround from the $29 million adjusted EBITDA loss recorded in the prior year. The company's full-year revenue grew 53% to $260 million, demonstrating accelerating growth momentum in the competitive digital health market.
"This quarter represents a pivotal milestone for Omada as we achieved profitability earlier than expected, while simultaneously accelerating our growth trajectory," the company said in its earnings announcement.
The strong performance was driven primarily by explosive growth in members using GLP-1 weight loss medications, which tripled to more than 150,000. Total membership increased 55% to 886,000, positioning Omada as a key player in the rapidly expanding digital chronic disease management space.
Omada's momentum prompted management to raise guidance for the 2026 fiscal year, projecting revenue of $312 million to $322 million, representing 22% year-over-year growth at the midpoint. The company also forecast adjusted EBITDA of $7 million to $15 million, signaling confidence in its ability to maintain profitability while scaling.
The earnings beat and profitability milestone arrive at a critical juncture for the digital health sector, which has faced increasing scrutiny from investors following the pandemic-era boom that led to inflated valuations across the industry. Many digital health companies have struggled to demonstrate path to profitability, making Omada's achievement particularly notable.
Prior to the earnings release, analysts maintained a bullish outlook on Omada, with 9 of 11 analysts rating the stock as either strong buy or buy and an average price target of $26.27, according to market data. The shares, which closed at $13.60 on Thursday, have traded in a 52-week range of $10.28 to $28.40, reflecting significant volatility as the company has worked to prove its business model.
Institutional investors have taken notice of Omada's progress, with approximately 80% of shares held by institutional investors. The company's market capitalization stands at approximately $747 million.
The GLP-1 growth story has become central to Omada's investment thesis as pharmaceutical giants like Novo Nordisk and Eli Lilly have struggled to meet surging demand for weight loss medications including Wegovy, Ozempic, and Zepbound. Healthcare providers and employers are increasingly turning to digital platforms to manage the clinical and behavioral aspects of GLP-1 treatment, creating a significant opportunity for companies like Omada that offer comprehensive virtual care programs.
Looking ahead, investors will be watching closely whether Omada can maintain its growth trajectory while expanding margins, as well as how effectively it can differentiate its offerings from competitors in the increasingly crowded digital health landscape. The company's ability to integrate with GLP-1 providers and demonstrate positive health outcomes for members will be key factors in sustaining its momentum.
The fourth-quarter results represent a vindication for management's strategy and provide evidence that digital health companies can achieve scale without sacrificing profitability—a combination that has proven elusive for many in the sector.